We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.57B
AUM Growth
+$29.7M
Cap. Flow
-$123M
Cap. Flow %
-7.84%
Top 10 Hldgs %
52.92%
Holding
277
New
83
Increased
54
Reduced
60
Closed
62

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.2M
2
MNKD icon
MannKind Corp
MNKD
+$15.2M
3
ABUS icon
Arbutus Biopharma
ABUS
+$4.32M
4
TWTR
Twitter, Inc.
TWTR
+$3.59M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.08M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.5M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$10.9M
3
GILD icon
Gilead Sciences
GILD
+$5.35M
4
AGEN
Agenus
AGEN
+$4.63M
5
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 9.13%
2 Communication Services 0.29%
3 Materials 0.04%
4 Financials 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TWTR
51
DELISTED
Twitter, Inc.
TWTR
$4.6M 0.29%
+72,300
New +$3.59M
MNTA
52
CALL
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$4.57M 0.29%
2,587
+2,065
+396% +$34.7K
RXII
53
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
$4.52M 0.29%
9,121
+1,131
+14% +$561K
SRPT icon
54
CALL
Sarepta Therapeutics
SRPT
$1.63B
$4.29M 0.27%
2,107
-602
-22% -$17.9K
ARNA
55
PUT
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.28M 0.27%
732
+455
+164% +$23.8K
ABUS icon
56
Arbutus Biopharma
ABUS
$871M
$4.14M 0.26%
+519,200
New +$4.32M
IMNN icon
57
PUT
Imunon
IMNN
$6.43M
$3.64M 0.23%
3
+2
+200% +$24K
CELG
58
CALL
DELISTED
Celgene Corp
CELG
$3.55M 0.23%
420
-1,194
-74% -$94.5K
INSM icon
59
CALL
Insmed
INSM
$22.6B
$3.39M 0.22%
+1,991
New +$30.5K
ARIA
60
CALL
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$3.33M 0.21%
4,880
+4,010
+461% +$21.6K
ACHV icon
61
Achieve Life Sciences
ACHV
$634M
$2.94M 0.19%
160
-27
-14% -$474K
INSM icon
62
PUT
Insmed
INSM
$22.6B
$2.94M 0.19%
1,727
+287
+20% +$4.39K
CEMP
63
DELISTED
Cempra, Inc.
CEMP
$2.94M 0.19%
237,000
+88,428
+60% +$1.07M
XOMA
64
DELISTED
Xoma
XOMA
$2.78M 0.18%
20,670
-2,114
-9% -$213K
SSKN
65
DELISTED
Strata Skin Sciences
SSKN
$2.75M 0.18%
+8,581
New +$3.07M
AVEO
66
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.74M 0.17%
+149,012
New +$2.98M
ABBV icon
67
CALL
AbbVie
ABBV
$465B
$2.73M 0.17%
+517
New +$25.4K
ITMN
68
PUT
DELISTED
INTERMUNE INC
ITMN
$2.71M 0.17%
1,838
+149
+9% +$2.06K
TEVA icon
69
CALL
Teva Pharmaceuticals
TEVA
$36.9B
$2.67M 0.17%
667
– –
DMK
70
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$2.6M 0.17%
+5,815
New +$2.55M
CBST
71
CALL
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$2.59M 0.17%
1,329
-869
-40% -$56.3K
KYTH
72
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$2.47M 0.16%
+66,200
New +$2.75M
EXEL icon
73
CALL
Exelixis
EXEL
$14.2B
$2.43M 0.15%
3,960
-207
-5% -$1.14K
ENTA icon
74
Enanta Pharmaceuticals
ENTA
$367M
$2.35M 0.15%
+85,946
New +$2.08M
IMNN icon
75
CALL
Imunon
IMNN
$6.43M
$2.33M 0.15%
+2
New +$24K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2013 Portfolio in Review

As of Q4 2013, Sabby Management held 277 positions worth $1.57B, up 1.9% from $1.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $123M in Q4 2013, closing 62 positions and reducing 60 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $23.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.1% of assets, down from 10% a quarter earlier, followed by Communication Services and Materials.

Against the trend, Sabby Management opened a new position in Arbutus Biopharma worth $4.14M.

  • Sabby Management's largest Q4 2013 buy was Arbutus Biopharma: 519,200 shares worth $4.14M.
  • Sabby Management added most to Teva Pharmaceuticals in Q4 2013, an estimated $17.2M increase.
  • Sabby Management's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $10.9M.
  • Sabby Management fully exited Vertex Pharmaceuticals in Q4 2013, selling an estimated $23.5M.
  • Sabby Management's ten largest holdings make up 53% of its $1.57B portfolio in Q4 2013.
  • Sabby Management opened 83 new positions and closed 62 in Q4 2013.
  • Sabby Management's portfolio value rose 1.9% quarter-over-quarter to $1.57B.

Based on Sabby Management's 13F filing for Q4 2013, filed 14 Feb 2014.